E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for AVEO Pharmaceuticals, Inc. > News item
Published on 1/16/2013 in the Prospect News PIPE Daily.

AVEO Pharmaceuticals intends to price public offering of common stock

JPMorgan, RBC Capital and Canaccord Genuity assist with financing

By Devika Patel

Knoxville, Tenn., Jan. 16 - AVEO Pharmaceuticals, Inc. said it will price a public offering of common stock. The deal will have a 15%, 30-day greenshoe.

J.P. Morgan Securities LLC is the bookrunning manager; RBC Capital Markets, LLC and Canaccord Genuity Inc. are co-lead managers.

AVEO is a Cambridge, Mass.-based biopharmaceutical company that is developing cancer therapeutics.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.